• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Ventyx Biosciences Inc.

    9/30/24 4:40:23 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTYX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001851194
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Ventyx Biosciences, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Ventyx Biosciences, Inc.
    Street Address 1 Street Address 2
    12790 EL CAMINO REAL, SUITE 200
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    SAN DIEGO CALIFORNIA 92130 (858) 945-2393

    3. Related Persons

    Last Name First Name Middle Name
    Mohan Raju
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Nuss John
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Subramaniam Somasundaram
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Moore Matthew
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Forman Mark S.
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gujrathi Sheila
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cadoret-Manier Onaiza
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hulme Allison
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    White William
    Street Address 1 Street Address 2
    c/o Ventyx Biosciences, Inc. 12790 El Camino Real Ste 200
    City State/Province/Country ZIP/PostalCode
    San Diego CALIFORNIA 92130
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
    X
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-09-23    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $26,999,940 USD
    or    Indefinite
    Total Amount Sold $26,999,940 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Ventyx Biosciences, Inc. /s/ Raju Mohan Raju Mohan Chief Executive Officer 2024-09-30

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $VTYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTYX

    DatePrice TargetRatingAnalyst
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    3/12/2024$12.00Perform → Outperform
    Oppenheimer
    3/12/2024$7.00 → $16.00Equal Weight → Overweight
    Wells Fargo
    11/7/2023$46.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    11/7/2023Outperform → Perform
    Oppenheimer
    11/7/2023Buy → Neutral
    H.C. Wainwright
    11/7/2023$6.00Buy → Hold
    Stifel
    11/7/2023$77.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $VTYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Nuss John sold $97,840 worth of shares (12,675 units at $7.72) and converted options into 34,930 shares, increasing direct ownership by 5% to 489,481 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/19/25 4:15:07 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO AND PRESIDENT Mohan Raju converted options into 116,668 shares and sold $365,461 worth of shares (47,345 units at $7.72), increasing direct ownership by 3% to 2,372,863 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/19/25 4:15:09 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Forman Mark S was granted 3,000 shares, increasing direct ownership by 100% to 6,000 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/19/25 4:30:10 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.

    SCHEDULE 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/6/26 4:13:53 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ventyx Biosciences Inc.

    SCHEDULE 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)

    2/5/26 4:53:27 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFM14A filed by Ventyx Biosciences Inc.

    DEFM14A - Ventyx Biosciences, Inc. (0001851194) (Filer)

    2/2/26 4:05:24 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

    Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (NASDAQ:VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation acr

    1/7/26 4:17:00 PM ET
    $LLY
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Provides Clinical and Corporate Updates

    Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx's R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerativ

    12/2/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

    SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fireside ChatDate: Wednesday, December 3, 2025Time: 4:00 – 4:25 PM ET A live webcast of the event will be available In the Investors and News section of the Ventyx website at https://ventyxbio.com/. A w

    12/1/25 7:02:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Ventyx Biosciences from Perform to Outperform and set a new price target of $12.00

    3/12/24 7:35:44 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Ventyx Biosciences from Equal Weight to Overweight and set a new price target of $16.00 from $7.00 previously

    3/12/24 7:35:12 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gujrathi Sheila bought $300,573 worth of shares (130,000 units at $2.31) (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    12/26/24 8:05:18 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO AND PRESIDENT Mohan Raju bought $959,889 worth of shares (500,000 units at $1.92), increasing direct ownership by 30% to 2,175,028 units (SEC Form 4)

    4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)

    11/25/24 9:07:34 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Leadership Updates

    Live Leadership Updates

    View All

    Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

    Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD

    4/1/25 7:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

    A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie

    8/8/24 4:01:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

    SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to

    5/16/24 8:00:00 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 3:06:49 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 8:57:39 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTYX
    Financials

    Live finance-specific insights

    View All

    Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

    VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semaglutide VTX3232 was safe and well tolerated both as a monotherapy and add-on to semaglutide in this studyVentyx to hold conference call and webcast 4:30pm ET on Wednesday, October 22nd SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences,

    10/22/25 4:02:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

    Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi

    5/9/24 4:01:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)

    5/2/24 4:05:00 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care